Month: March 2024

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsNet revenue increased by 6.3% year-over-year (“Y-o-Y”) to RMB2,556.5 million (US$360.1 million) in the fourth quarter of 2023 (4Q2022: RMB2,404.0 million). Net loss was RMB3,164.6 million (US$445.7 million) in the fourth quarter of 2023 (4Q2022: net loss of RMB177.9 million). Adjusted EBITDA (non-GAAP) increased by 5.7% Y-o-Y to RMB1,132.6 million (US$159.5 million) in the fourth quarter of 2023 (4Q2022: RMB1,071.5 million). See “Non-GAAP Disclosure”...

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in H1 2024.  $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “Aprea...

– Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 –– On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 – – 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 –– Webcast Conference Call Scheduled Today at 8:00 a.m. ET – PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below. A number...

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company’s ongoing phase 2 trial in patients with melanoma Mural Oncology intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 in 2024 The company reiterates cash runway projection into 4Q 2025 WALTHAM, Mass. and DUBLIN, Ireland, March 26, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address...

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $306.1 million as of Dec. 31, 2023, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ETCHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported...

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) —  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress. “Among...

SHOHAM, Israel, March 26, 2024 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced financial results for the year ended December 31, 2023. Recent Operational Highlights:Received initial production-scale order in Q3 2023 followed by additional quantity-increase order in Q4 2023 from U.S. Tier-1 drone manufacturer which delivers to the U.S. Department of Defense (“DOD”) Chosen by the U.S.DOD for Soldiers’ Next Generation Wearable Tactical AI-Enhanced Mission Kits Secured $900,000 initial production-scale order from global Tier-1 Israeli-based manufacturer for loitering (kamikaze) drones platform Secured initial production-scale order from another global Tier-1 Israeli-based manufacturer for use by the...